Novo Nordisk has entered into a license agreement with Deep Apple Therapeutics v...
Nearly a decade after selling Medivation to Pfizer for $14B, David Hung, M.D., i...
Insmed has announced favorable outcomes from its phase 2b clinical trial assessi...
The U.S. Food and Drug Administration has approved Merck’s monoclonal antibody, ...
Seyltx, a clinical-stage biotherapeutics company based in Cambridge, Massachuset...
Ascletis Pharma has announced topline results from a phase 3 clinical trial eval...
RegenXBio has released an update on its Phase 1/2 clinical trial evaluating the ...
Amgen Inc. has reported positive interim results from its Phase 3 DeLLphi-304 cl...
France’s Sanofi has agreed to acquire U.S.-based Blueprint Medicines Corporation...
Sanofi and Regeneron’s experimental COPD drug, itepekimab, produced mixed result...
In its inaugural worldwide phase 3 results, the PD-1xVEGF bispecific antibody iv...
Nearly all patients with depression who were administered Gilgamesh Pharmaceutic...
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Rocket...
Sanofi is acquiring Vigil Neuroscience for $470 million to expand its Alzheimer’...
Gilead Sciences has acquired exclusive ownership of two arenavirus-based immunot...
The Food and Drug Administration (FDA) has introduced more rigorous regulatory r...
